SCLC-J1, a novel small cell lung cancer cell line

Small cell lung cancer (SCLC) is a type of high-grade neuroendocrine carcinoma. It initially responds to chemotherapy but rapidly becomes chemoresistant and it is highly proliferative. The prognosis in SCLC is poor. We have established a novel SCLC cell line, SCLC-J1, from a malignant pleural effusi...

Full description

Saved in:
Bibliographic Details
Published in:Biochemistry and biophysics reports 2021-09, Vol.27, p.101089-101089, Article 101089
Main Authors: Ohara, Kazuo, Kinoshita, Shintaro, Ando, Jun, Azusawa, Yoko, Ishii, Midori, Harada, Sakiko, Mitsuishi, Yoichiro, Asao, Tetsuhiko, Tajima, Ken, Yamamoto, Taketsugu, Takahashi, Fumiyuki, Komatsu, Norio, Takahashi, Kazuhisa, Ando, Miki
Format: Article
Language:English
Subjects:
B7-H3
DLL3
Established SCLC cell line
GD2
Small cell lung cancer
Somatic mutations
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small cell lung cancer (SCLC) is a type of high-grade neuroendocrine carcinoma. It initially responds to chemotherapy but rapidly becomes chemoresistant and it is highly proliferative. The prognosis in SCLC is poor. We have established a novel SCLC cell line, SCLC-J1, from a malignant pleural effusion in a patient with advanced SCLC. SCLC-J1 cells express ganglioside GD2, CD276, and Delta-like protein 3. RB1 is lost. These features of the new SCLC cell line may be useful in understanding the cellular and molecular biology of SCLC and in designing better treatment. •A novel small lung cancer cell line, SCLC-J1, was successfully established.•SCLC-J1 cells express the tumor-specific antigens ganglioside GD2, CD276, and Delta-like protein 3. RB1 is lost.•SCLC-J1 will provide insights into SCLC biology that may permit better therapeutic targeting.
ISSN:2405-5808
2405-5808
DOI:10.1016/j.bbrep.2021.101089